| Comment | 52.800 | Paul Harris, CFA | One of the better performing drug companies over the last several years, but suffers from what many of the drug companies suffer from; much more difficult to come up with new drugs. Well run company. | 2008-05-22 | |
| Comment | 49.530 | David Driscoll | Good quality company. Came down similar to most pharmaceuticals. A lot of them are having pipeline problems in getting new products to market. Relative to the US, it has a far better portfolio. OK as an entry point but he believes the sector could drop further so he would suggest you use a limit order down in a $40 range. | 2008-04-23 | |
| DON'T BUY | 52.140 | David Driscoll | Has been suffering, while other drug companies have been doing very well. | 2007-10-25 | |
| Comment | 56.080 | Mark Grammer | Prefers Rosch (ROCM-Q) over this one. | 2007-06-06 | |
| Comment | 55.100 | Charles Lannon | One of the more expensive healthcare stocks, which reflects the quality of its pipeline. Would prefer Johnson & Johnson (JNJ-N). | 2007-03-01 | |
| BUY | 58.300 | Norman Levine | The European drug stocks are cheaper than the US ones and probably have a better regulatory outlook, so owning this is not a bad idea. | 2006-12-20 | |
| DON'T BUY | 55.990 | David Driscoll | The leading European pharmaceutical. Has its good points, but is in a lot of competition with the other majors. Will probably come into a little bit of a lull. | 2006-07-26 | |
| BUY | 49.020 | Kevin Vandermeer, B.Comm, CFA | We really like it. One of the few pharma companies that have a generics division embedded in it. They continue to move in the generics area because they see growth in that sector. | 2005-03-11 | |
| TOP PICK | 45.760 | Samuel D. Isaly | Growing very well. Their biggest drug is for high blood pressure but also have a good product line for cancer treatment. Not many patent exposures in the near-term. | 2004-08-13 | |
| BUY | 34.930 | David Driscoll | Safe, big and will make money. | 2001-06-22 | |
Experts that have talked about Novartis AG